Clinical trials
Lung Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting lung cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,798 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06481592RecruitingPhase 2
Study of lifileucel for advanced endometrial cancer
This trial tests an experimental cell therapy called lifileucel, made from your own immune cells, for advanced endometrial cancer that has progressed after standard treatments. It aims to shrink tumors and slow the disease.
Phoenix, ArizonaAges 18–70 - NCT06480552RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT06494540Recruiting
TDC treatment for advanced non-squamous lung cancer
This study is looking at how well a new treatment called TDC (which includes durvalumab and chemotherapy) works for people with a certain type of advanced lung cancer that has spread and has specific genetic features. It aims to see if this treatment is effective and safe in the real world, and it might be an option if you are starting this therapy anyway.
Bad HomburgAges 18–120 - NCT06483555RecruitingPhase 1/Phase 2
Drug combo for basal-like pancreatic cancer
This trial tests a combination of three drugs (gemcitabine, erlotinib, and nab-paclitaxel) for people with a specific type of pancreatic cancer called 'basal-like' PDAC. It aims to see if this targeted approach works better than standard treatment.
Chapel Hill, North CarolinaAges 18 years+ - NCT06460298RecruitingPhase 1/Phase 2
ProAgio and gemcitabine for triple-negative breast cancer that has spread
This trial tests a new drug called ProAgio combined with the chemotherapy gemcitabine for people with triple-negative breast cancer that has spread to other parts of the body. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Atlanta, GeorgiaAges 18 years+ - NCT06467357RecruitingPhase 3
New drug combo for advanced bile duct cancer with HER2
This study tests a new combination of drugs for advanced bile duct cancer that has not been treated yet and shows a protein called HER2. It compares the new combination to the standard treatment to see if it works better or has fewer side effects.
Scottsdale, ArizonaAges 18–99 - NCT06459791Recruiting
Personalized treatment for advanced breast cancer using lab-grown tumor models
This trial tests a personalized approach to cancer treatment. Doctors will grow a ‘mini-tumor’ from a biopsy of your cancer in the lab to help find the best therapy for you. It is for people with advanced breast cancer that has not responded well to standard treatments.
ParisAges 18 years+ - NCT04159142RecruitingPhase 2
Testing two chemo combos for advanced triple-negative breast cancer
This Phase 2 trial compares two chemotherapy combinations to see which works better for advanced triple-negative breast cancer. You would be asked to join one treatment arm based on study assignment and be followed for response and side effects.
Shijiazhuang, HebeiAges 18–70 - NCT06445062RecruitingPhase 1/Phase 2
RAS-targeting drugs for gastrointestinal cancers
This trial tests new drugs that target a specific genetic change (RAS) in gastrointestinal cancers like pancreatic and colorectal cancer. The goal is to see if these drugs can shrink or slow down the cancer.
Chandler, ArizonaAges 18 years+ - NCT06457503RecruitingPhase 4
Toripalimab plus chemo for advanced nasopharyngeal cancer
This trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy (cisplatin and gemcitabine) can help people whose nasopharyngeal cancer has come back or spread. It is for those who haven't yet received other treatments for this advanced stage.
Little Rock, ArkansasAges 12 years+ - NCT06458712RecruitingPhase 1
Testing a new drug for advanced cancers with gene changes
This study tests a new oral drug, DSB2455, for people with advanced breast, prostate, ovarian, or pancreatic cancers that have certain gene changes. It aims to see if the drug is safe and whether it helps shrink or control the cancer.
Sacramento, CaliforniaAges 18 years+ - NCT06446401Recruiting
Triple vs double therapy for widespread prostate cancer
This trial compares two treatment approaches for men whose prostate cancer has spread widely and is still responding to hormone therapy. It tests whether using three drugs together (triple therapy) works better than two drugs (double therapy) to control the cancer longer.
Uppsala, Region UppsalaAges 18 years+ - NCT06457906RecruitingPhase 3
Focused radiation vs whole brain radiation for up to 10 lung cancer brain spots
This trial compares two types of radiation for people with small cell lung cancer that has spread to the brain (10 or fewer spots). One approach uses focused radiation only on the tumors, the other treats the whole brain while trying to protect memory. The goal is to see which works better with fewer side effects.
Beijing, Beijing MunicipalityAges 18–80 - NCT06079983RecruitingPhase 3
JSKN003 vs. doctor's choice for HER2-low breast cancer
This trial compares a new experimental drug, JSKN003, to standard treatments chosen by your doctor for advanced breast cancer that tests as HER2-low (IHC 1+ or 2+ but not amplified). It's for people whose cancer has spread or can't be removed and who have already had one or two lines of chemotherapy.
Guangzhou, GuangdongAges 18 years+ - NCT06439888RecruitingPhase 1/Phase 2
Immune cells plus radiation for limited-stage cancer spread
This trial tests whether giving immune-supporting cells (lymphocytes) alongside focused radiation (SBRT) can help control limited cancer spread. People with 1 to 5 small tumors that can all be radiated within two weeks may be eligible.
LyonAges 18 years+ - NCT06439485RecruitingPhase 1/Phase 2
Combination drug therapy for advanced bile duct cancer with FGFR2 change
This trial tests a combination of three drugs (pemigatinib, atezolizumab, and bevacizumab) for people with advanced bile duct cancer that has a specific genetic change called FGFR2 fusion. The goal is to see if this combination can shrink or control the cancer when standard treatments have stopped working.
Houston, TexasAges 18 years+ - NCT06429813Recruiting
Remote exercise program for men with metastatic prostate cancer
This trial tests whether a remotely supervised exercise program (walking and stationary cycling) can help men with metastatic prostate cancer who are starting hormone therapy. Participation involves following an exercise plan at home and may help manage side effects.
Charlottesville, VirginiaAges 18 years+ - NCT06424626Enrolling by invitationPhase 1
Testing new drug combos for advanced mucosal melanoma
This trial tests two experimental drugs, AK104 or AK112, combined with a targeted therapy called axitinib for people with metastatic mucosal melanoma (a rare type of skin cancer that has spread). The goal is to see if these combinations can shrink tumors or slow the cancer's growth.
BeijingAges 18 years+ - NCT06417801Recruiting
Study of ESR1 gene changes in blood in advanced breast cancer
This study looks for changes in the ESR1 gene in the blood of people with advanced HR+/HER2- breast cancer. It compares these blood test results with tumor tissue results to learn more about the cancer.
Salvador, Estado de BahiaAges 18–100 - NCT06419179Enrolling by invitationPhase 2
Maintenance therapy for HRD-positive small-cell lung cancer
This trial tests whether a combination of two medications, durvalumab and olaparib, can help keep your extensive-stage small-cell lung cancer from coming back after standard first-line treatment. It is for people whose tumors have a specific genetic feature called HRD.
Cologne, North Rhine-WestphaliaAges 18–120 - NCT06389123RecruitingPhase 1
Targeted radiation for metastatic cancer that stopped responding
This study tests a new approach that first uses a special scan to find cancer cells that have a specific marker, then delivers targeted radiation to those cells. It is designed for people with advanced solid tumors that have spread and stopped responding to standard treatments.
Sacramento, CaliforniaAges 18 years+ - NCT06253611RecruitingPhase 2
Probiotic plus immunotherapy and chemo for stomach cancer
This trial tests a new combination for advanced stomach cancer: an experimental probiotic (EXL01) plus standard immunotherapy (nivolumab) and chemotherapy (FOLFOX). It is for people whose tumors have a high PD-L1 marker and who have not received prior treatment for advanced disease.
AngersAges 18 years+ - NCT06306612Recruiting
Surgery plus hormone therapy for advanced prostate cancer
This trial tests whether removing the prostate (surgery) plus standard hormone therapy and chemotherapy can help men whose prostate cancer has spread to many places in the body. It is for men who have not yet had treatment for their cancer.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT06302621RecruitingPhase 1
Pemigatinib plus afatinib for advanced solid tumors with FGFR changes
This trial tests two targeted drugs, pemigatinib and afatinib, together for people with advanced solid tumors that have a specific FGFR genetic change. It may be an option if standard treatments have stopped working or aren't available.
Boston, MassachusettsAges 18 years+
Hear when a new Lung Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,798 recruiting lung cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Liver Cancer (Locally Advanced or Metastatic)
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.